Drug Trial Radar · NCT05559476
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
Last checked: Nov 20, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,029
Actual
Start
Oct 20, 2022
Primary completion
Mar 7, 2023
Study completion Aug 15, 2023
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65 years and above compared to separate administration of the vaccines.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccineBiological
RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
FLU HD vaccineBiological
FLU HD vaccine administered intramuscularly in the deltoid region of the dominant arm (Co-Ad Group) or the non-dominant arm (Control Group).
Primary outcomes
What the sponsor says the trial is designed to measure.
- RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs)Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)
- Hemagglutinin Inhibition (HI) Titers for 4 FLU Vaccine Strains Expressed as Group GMTsTime frame: At 1 month after the FLU vaccine dose (Day 31 for both groups)
- RSV-B Neutralizing Titers Expressed as Group GMTsTime frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)
Locations
46 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Tempe, Arizona
GSK Investigational Site
Canoga Park, California
GSK Investigational Site
Colton, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Walnut Creek, California
GSK Investigational Site
Aurora, Colorado
GSK Investigational Site
Coral Gables, Florida
GSK Investigational Site
Fort Myers, Florida
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Immokalee, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Sandy Springs, Georgia
GSK Investigational Site
Savannah, Georgia
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Evansville, Indiana
GSK Investigational Site
Mishawaka, Indiana
GSK Investigational Site
Valparaiso, Indiana
GSK Investigational Site
Ames, Iowa
GSK Investigational Site
El Dorado, Kansas
GSK Investigational Site
Methuen, Massachusetts
GSK Investigational Site
Minneapolis, Minnesota
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Grand Island, Nebraska
GSK Investigational Site
Papillion, Nebraska
GSK Investigational Site
North Las Vegas, Nevada
GSK Investigational Site
Warren Township, New Jersey
GSK Investigational Site
Hickory, North Carolina
GSK Investigational Site
Rocky Mount, North Carolina
GSK Investigational Site
Wilmington, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Edmond, Oklahoma
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Columbia, South Carolina
GSK Investigational Site
North Charleston, South Carolina
GSK Investigational Site
Spartanburg, South Carolina
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.